Trailing-twelve-month (TTM) revenue is $42.28 Million with a year-over-year growth of +25.86%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $8,861,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $10,410,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-17 |
| Q1 FY2026Period ended 2026-03-31 | $12,128,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13 |
| Q2 FY2026Period ended 2026-06-30 | $10,880,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-03 |
| TTM revenue | $42,279,000 |
Current P/S: $336,783,208 market capitalization ÷ $42,279,000 TTM revenue = 7.97x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T14:14:37.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $10.88M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:16:12.704Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Biologics and Drug Delivery - Disposable Products | N/A | $3M | $4M | $2M | $6M | $7M |
| Biologics and Drug Delivery - Services | N/A | $3M |
$42.28M
$42.28 Million
+25.86%
vs. $33.59M a year ago (TTM)
+23.57%
5 Year compound annual growth rate
1 Year
+25.86%
3 Year
+24.89%
5 Year
+23.57%
10 Year
+23.19%
15 Year
+19.15%
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $36.97M | +$5.58M | +17.78% |
| 2024 | $31.39M | +$7.43M | +31.04% |
| 2023 | $23.95M | +$3.40M | +16.56% |
| 2022 | $20.55M | +$4.25M | +26.09% |
| 2021 | $16.30M | +$3.47M | +27.05% |
| 2020 |
TTM Growth
+25.86%
3-Year CAGR
+24.89%
5-Year CAGR
+23.57%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T14:16:12.704Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| N/A |
| N/A |
| Biologics and Drug Delivery Revenue | $5M | $7M | $9M | $14M | $17M | $19M |
|---|
| Capital Equipment and Software - Services | N/A | $569,000 | $795,000 | $973,000 | $1M | $1M |
|---|
| Capital Equipment and Software - Systems and Software Products | N/A | $864,000 | $2M | $860,000 | $3M | $2M |
|---|
| Capital Equipment and Software Revenue | $1M | $1M | $2M | $2M | $4M | $3M |
|---|
| Functional Neurosurgery Navigation and Therapy | N/A | $8M | $9M | $9M | N/A | N/A |
|---|
| Functional Neurosurgery Navigation and Therapy - Disposable Products | N/A | $8M | $8M | $8M | N/A | N/A |
|---|
| Functional Neurosurgery Navigation and Therapy - Services | N/A | $375,000 | $2M | $931,000 | N/A | N/A |
|---|
| $12.83M |
| +$1.61M |
| +14.37% |
| 2019 | $11.22M | +$3.86M | +52.54% |
| 2018 | $7.35M | ($26,259) | (0.36%) |
| 2017 | $7.38M | +$1.63M | +28.35% |
| 2016 | $5.75M | +$1.16M | +25.15% |
